David W. Kimberlin, M.D.

Associate Professor of Pediatrics

Division of Pediatric Infectious Diseases

The University of Alabama at Birmingham

1600 Seventh Avenue South, CHB 303

Birmingham, AL  35233

Phone:  205-934-5316

FAX:    205-975-9972

e-mail:  dkimberlin@peds.uab.edu

Since joining the faculty at The University of Alabama at Birmingham in 1996, Dr. David Kimberlin has overseen all pediatric studies conducted by the National Institute of Allergy and Infectious Diseases’ Collaborative Antiviral Study Group, and serves as Co-PI on the CASG contract.  The CASG is an NIH-sponsored, multicenter, international organization of academic medical centers that conducts antiviral therapeutic trials for orphan diseases which do not receive the attention and research investments of pharmaceutical companies.  It consists of approximately 35 centers in the United States, Canada, the United Kingdom, and Sweden.  The University of Alabama at Birmingham has served as the CASG Central Unit since its inception in 1972.  Since 1996, Dr. Kimberlin has directly overseen and managed international CASG investigations of the treatment of neonatal herpes disease, congenital cytomegalovirus disease, neonatal and infantile enteroviral disease, and juvenile-onset recurrent respiratory papillomatosis.

Dr. Kimberlin also serves as the Medical Director of the University of Alabama at Birmingham Pediatric Clinical Trials Office, and he is the Associate Director of the University of Alabama at Birmingham General Clinical Research Center (GCRC).

.